[{"address1": "One World Trade Center", "address2": "22nd Floor", "city": "New York", "state": "NY", "zip": "10007", "country": "United States", "phone": "212 332 3241", "fax": "212 320 0245", "website": "https://www.axsome.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.", "fullTimeEmployees": 589, "companyOfficers": [{"maxAge": 1, "name": "Dr. Herriot  Tabuteau M.D.", "age": 55, "title": "Founder, Chairman, CEO & President", "yearBorn": 1968, "fiscalYear": 2023, "totalPay": 1395461, "exercisedValue": 0, "unexercisedValue": 99836880}, {"maxAge": 1, "name": "Mr. Nick  Pizzie CPA, M.B.A.", "age": 48, "title": "Chief Financial Officer", "yearBorn": 1975, "fiscalYear": 2023, "totalPay": 765483, "exercisedValue": 0, "unexercisedValue": 21085196}, {"maxAge": 1, "name": "Mr. Mark L. Jacobson M.A.", "age": 40, "title": "Chief Operating Officer", "yearBorn": 1983, "fiscalYear": 2023, "totalPay": 835837, "exercisedValue": 0, "unexercisedValue": 32287852}, {"maxAge": 1, "name": "Mr. Hunter  Murdock Esq.", "age": 43, "title": "General Counsel & Secretary", "yearBorn": 1980, "fiscalYear": 2023, "totalPay": 757312, "exercisedValue": 0, "unexercisedValue": 2159036}, {"maxAge": 1, "name": "Mr. Ari  Maizel", "title": "Executive VP & Head of Commercial", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 8, "boardRisk": 8, "compensationRisk": 8, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1725148800, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 95.56, "open": 95.88, "dayLow": 93.34, "dayHigh": 96.98, "regularMarketPreviousClose": 95.56, "regularMarketOpen": 95.88, "regularMarketDayLow": 93.34, "regularMarketDayHigh": 96.98, "beta": 1.255, "forwardPE": -47.558376, "volume": 507380, "regularMarketVolume": 507380, "averageVolume": 640579, "averageVolume10days": 409330, "averageDailyVolume10Day": 409330, "bid": 93.42, "ask": 93.76, "bidSize": 100, "askSize": 200, "marketCap": 4497138688, "fiftyTwoWeekLow": 55.02, "fiftyTwoWeekHigh": 98.4, "priceToSalesTrailing12Months": 15.42816, "fiftyDayAverage": 84.9208, "twoHundredDayAverage": 79.024925, "currency": "USD", "enterpriseValue": 4463042560, "profitMargins": -1.05854, "floatShares": 35773593, "sharesOutstanding": 48000200, "sharesShort": 7665579, "sharesShortPriorMonth": 8282197, "sharesShortPreviousMonthDate": 1721001600, "dateShortInterest": 1723680000, "sharesPercentSharesOut": 0.1597, "heldPercentInsiders": 0.1684, "heldPercentInstitutions": 0.86059, "shortRatio": 14.63, "shortPercentOfFloat": 0.1916, "impliedSharesOutstanding": 48000200, "bookValue": 2.152, "priceToBook": 43.536247, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -308552000, "trailingEps": -6.58, "forwardEps": -1.97, "pegRatio": -0.09, "enterpriseToRevenue": 15.311, "enterpriseToEbitda": -17.075, "52WeekChange": 0.17366743, "SandP52WeekChange": 0.24014747, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "AXSM", "underlyingSymbol": "AXSM", "shortName": "Axsome Therapeutics, Inc.", "longName": "Axsome Therapeutics, Inc.", "firstTradeDateEpochUtc": 1447943400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "dc312fd5-deeb-376b-9b93-11451c06c191", "messageBoardId": "finmb_241907563", "gmtOffSetMilliseconds": -14400000, "currentPrice": 93.69, "targetHighPrice": 180.0, "targetLowPrice": 100.0, "targetMeanPrice": 125.88, "targetMedianPrice": 117.5, "recommendationMean": 1.6, "recommendationKey": "buy", "numberOfAnalystOpinions": 16, "totalCash": 315656992, "totalCashPerShare": 6.576, "ebitda": -261380992, "totalDebt": 191800000, "quickRatio": 2.337, "currentRatio": 2.482, "totalRevenue": 291488992, "debtToEquity": 186.482, "revenuePerShare": 6.154, "returnOnAssets": -0.2823, "returnOnEquity": -1.61691, "freeCashflow": -77132496, "operatingCashflow": -167487008, "revenueGrowth": 0.867, "grossMargins": 0.90304, "ebitdaMargins": -0.89671, "operatingMargins": -0.87059, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-09-05"}]